A new way to deliver mRNA vaccines using injectable hydrogels
Injectable Hydrogel Depots for Self-replicating mRNA Vaccine Delivery
This study is testing a new type of gel that can be injected just once to deliver a special vaccine that helps your body fight off infections from Staphylococcus aureus, making it easier and more effective to stay protected without needing multiple shots.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10849877 on NIH RePORTER |
What this research studies
This research focuses on developing an innovative injectable hydrogel that can deliver self-replicating mRNA vaccines to help combat infections caused by Staphylococcus aureus. The approach involves creating biodegradable gel depots that encapsulate the mRNA, allowing for a single injection that provides long-lasting immunity, rather than requiring multiple doses. By using advanced materials, the goal is to enhance the immune response and improve patient outcomes against severe infections. This method aims to simplify vaccination processes and increase effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for Staphylococcus aureus infections, such as those with compromised immune systems or those undergoing procedures involving catheters or prosthetic devices.
Not a fit: Patients who are not at risk for Staphylococcus aureus infections or those who have already been vaccinated against it may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and convenient vaccination methods that significantly reduce the risk of severe infections from Staphylococcus aureus.
How similar studies have performed: Other research has shown promise in using biodegradable materials for vaccine delivery, suggesting that this approach could be effective.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Bryers, James D. — University of Washington
- Study coordinator: Bryers, James D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.